Form 4/A for STLN Starling Oncology, Inc.
Accepted 2025-04-28 00:00:00 ET · period of report 2025-03-26 · accession 0000935836-25-000296 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2025-04-28 | 2025-03-26 | STLN | Hively Brad | Dir | P - Purchase | $1.04 | +45.3K | 712.0K | +7% | +$47.1K |
| DA | 2025-04-28 | 2025-03-26 | STLN | Hively Brad | Dir | P - Purchase | $0.13 | +22.6K | 22.6K | New | +$2,943 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-26 | P | A | 45,280 | $1.04 | 712,033 | D | — | — | (F1) This amendment is filed to correct the number of shares of Common Stock and number of Common Warrants acquired by the reporting person in the transaction reported on the original Form 4 filed on March 28, 2025. As a result of this correction, the amount of securities beneficially owned following the reported transaction specified in Table I, Column 5 and Table II, Column 9 have also been corrected. (F4) Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250. |
| 2 | Derivative | Common Warrant | 2025-03-26 | P | A | 22,640 | $0.13 | 22,640 | D | $1.20 · 2025-03-26 to 2030-03-26 | 22,640 Common Stock | (F2) Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). (F1) This amendment is filed to correct the number of shares of Common Stock and number of Common Warrants acquired by the reporting person in the transaction reported on the original Form 4 filed on March 28, 2025. As a result of this correction, the amount of securities beneficially owned following the reported transaction specified in Table I, Column 5 and Table II, Column 9 have also been corrected. (F4) Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250. (F5) The reporting person may not exercise any portion of a Common Warrant to the extent that the reporting person would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Exchange Act. |